Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 13,269 |
|
|||||
| News | - | ||||||
| Day High | 2.915 | Low High |
|||||
| Day Low | 2.78 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Elutia Inc | ELUT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.11 | -3.81% | 2.78 | 16:03:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.88 | 2.78 | 2.915 | 2.78 | 2.89 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 72 | 13,269 | $ 2.82 | $ 37,464 | - | 1.10 - 4.1893 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:46:09 | 1 | $ 2.90 | USD |
Elutia Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 67.48M | 24.27M | - | 24.75M | -37.66M | -1.55 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Elutia News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ELUT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.01 | 3.03 | 2.78 | 2.89 | 3,757 | -0.23 | -7.64% |
| 1 Month | 3.14 | 3.20 | 2.7501 | 2.99 | 7,352 | -0.36 | -11.46% |
| 3 Months | 3.67 | 4.04 | 2.7501 | 3.44 | 14,346 | -0.89 | -24.25% |
| 6 Months | 1.22 | 4.1893 | 1.14 | 2.46 | 31,760 | 1.56 | 127.87% |
| 1 Year | 1.19 | 4.1893 | 1.10 | 1.70 | 194,820 | 1.59 | 133.61% |
| 3 Years | 1.19 | 4.1893 | 1.10 | 1.70 | 194,820 | 1.59 | 133.61% |
| 5 Years | 1.19 | 4.1893 | 1.10 | 1.70 | 194,820 | 1.59 | 133.61% |
Elutia Description
| Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection. |
